Litcius/Paper detail

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

Meletios Α. Dimopoulos, Hang Quach, María‐Victoria Mateos, Ola Landgren, Xavier Leleu, David S. Siegel, Katja Weisel, Hui Yang, Zandra Klippel, Anita Zahlten‐Kumeli, Saad Z. Usmani

2020The Lancet422 citationsDOI

Topics & Concepts

CarfilzomibDaratumumabMedicineDexamethasoneMultiple myelomaRefractory (planetary science)Adverse effectInternal medicineLenalidomideClinical endpointPopulationOncologyClinical trialEnvironmental healthPhysicsAstrobiologyMultiple Myeloma Research and TreatmentsCancer Mechanisms and TherapyBioactive Compounds in Plants
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study | Litcius